Remibrutinib beats teriflunomide in two phase 3 relapsing MS trials
Start here
The REMODEL-1 and REMODEL-2 randomised phase 3 trials tested remibrutinib, an oral BTK inhibitor, against teriflunomide in patients with relapsing multiple sclerosis. In both trials, remibrutinib was superior to teriflunomide on efficacy while maintaining a good safety profile. Published in The Lancet on 23 October 2026, the results support remibrutinib as a potential new oral treatment option for relapsing multiple sclerosis. Open questions include the full detail of the efficacy and safety data as regulators and clinicians weigh approval and positioning against existing oral therapies.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- statnews.comPickSTAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
In two Phase 3 trials in relapsing multiple sclerosis, Novartis' remibrutinib reduced the annualized relapse rate by 35.2% and 31.2% compared with Sanofi's Aubagio. Data from REMODEL-1 and REMODEL-2 were presented at MSToronto and published in the Lancet; there were no Hy's Law cases and rates of elevated liver enzymes were very low.
- thelancet.com[Articles] Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
In two randomised phase 3 trials, REMODEL-1 and REMODEL-2, remibrutinib was superior to teriflunomide in patients with relapsing multiple sclerosis and maintained a favourable safety profile. The findings support remibrutinib as a potential new oral treatment option for relapsing multiple sclerosis.
Heat trend for this story
Heat now 17·Peak in the comparable set 20 (Oct 24 01:00)·Change over 24h in the comparable set –·Participants now 2
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.